Feb 04, 2022
The discovery of new classes of highly effective drug therapy for prevalent kinds of cardiovascular diseases has witnessed spectacular success in recent decades. The widespread use of these cardiovascular drugs, combined with smoking cessation and nonpharmacological therapy, is thought to be responsible for decreas...
Read More...
Jan 31, 2022
Cardiovascular Diseases (CVDs), primarily constituting heart failure, ischemic heart disease, stroke, are considered as leading global cause of mortality and a major contributor to disability. Over the last 30 years, deaths and disabilities from Cardiovascular Disease have been steadily rising across the globe. Car...
Read More...
Nov 04, 2016
According to National Society of Health, approximately 26 million patients are suffering from heart failure worldwide, with the increased economic burden of USD 30.7 billionĀ each year. The advent of a novel class of drugs, i.e., the angiotensin receptor-neprilysin inhibitor, gives hope to the patients. Neprilysin is...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper